Federal prosecutors investigate pharma kickbacks; FDA to fast-track e-cigarette designed to curb teen use; Medtronic to acquire Mazor Robotics.
Amicus acquires rare disease gene therapy programs; Data shows black patients are underrepresented in clinical trials; Takeda acquires Molecular Templates.
AbbVie accused of kickbacks to push Humira; Opioid crisis becomes major midterm campaign theme; GSK hires former Boehringer Ingelheim chief medical officer.
Senate overwhelmingly passes opioid bill; Novo Nordisk plans layoffs in Denmark, China; Justice Department OKs Cigna’s acquisition of Express Scripts.
Gottlieb outlines reimbursement reforms for antimicrobial treatments; Teva’s migraine treatment wins FDA approval; Study finds daily low-dose aspirin risks for older individuals.
Nostrum CEO blames FDA for 400% price hike; Boehringer Ingelheim acquires biotech ViraTherapeutics; Scientists make breakthrough discovery with BRCA1 gene.
FDA threatens to ban flavored vapes; Cigna launches $250 million venture fund; Takeda shutters Chicago operations.
Nostrum CEO defends decision to hike antibiotic price; Appeals court rules Acorda patents for Ampyra are not valid; University patent battle over gene-editing technology concludes.
U.K. regulator rules MS drug too expensive; Memorial Sloan Kettering CEO demands more transparency from staff on financial relationships; Report: Family behind Purdue owns second opioid drugmaker.
Opioid-treatment patent award raises concerns; Senate to vote on opioid bill next week; Walgreens stocks up on Auvi-Q.
Justice Department closer to merger approvals; GSK cuts 650 jobs; Civica Rx names CEO.
Comcast veteran joins Amazon, Berkshire, JP Morgan health venture; Theranos to dissolve; Bayer mulls job cuts in R&D review.
Caplacizumab wins European approval; former Glaxo scientist pleads guilty to trade secret theft charge; FDA to hold hearing on boosting biologic competition.
AstraZeneca’s lupus drug fails to meet goals; FDA expands investigation into heart drugs; Lilly names new head of Oncology.
The first digital pill is rolling out to Medicaid patients; Narcan’s new owner sees an untapped market in schools; Medicare plans can decide which drug indication is covered.